Bayer’s new cell culture technology centre will focus on oncology, cardiology and additional specialty care. Credit: Bayer Corporation.

Bayer has committed $150m to build a cell culture technology centre at its pharmaceutical development and manufacturing site in Berkeley, California, US.

The new 40,000ft² single-use technology (SUT) biopharmaceutical manufacturing facility will support the development of biological therapies across various patient types. It will focus on oncology, cardiology and additional specialty care fields.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bayer’s existing Berkeley campus includes a recombinant Factor VIII manufacturing facility to produce haemophilia A treatments.

The new centre is expected to begin clinical production in 2021. It is intended to support pipeline candidates and also development of new assets resulting from the company’s partnerships.

Bayer Pharmaceuticals product supply executive vice-president and head Wolfram Carius said: “This investment allows Bayer to expand our biologics development and launch capabilities, as we advance our R&D programmes internally and through strategic collaborations.”

The company noted that the new facility will leverage automation, digital capabilities and single-use bioprocessing technologies to allow faster production of medicines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“This investment allows Bayer to expand its biologics development and launch capabilities.”

It has selected Fluor for design and construction, with GE Healthcare chosen to integrate its FlexFactory SUT technology platform into the centre.

Fluor will be responsible for engineering, procurement, construction management, commissioning, qualification and validation of the facility.

Integration of GE Healthcare’s FlexFactory platform will be carried out via a collaborative subcontract with Fluor. GE will also supply all major unit operations, systems, ancillary equipment and components.

Furthermore, Fluor will be responsible for process integration across the facility and all related utilities.

Fluor life sciences and advanced manufacturing business line president Juan Hernandez said: “The facility’s user-friendly, reconfigurable design will facilitate increased speed to market for new life-saving treatments.”

Bayer operates multiple innovation hubs worldwide, including the Berkeley pharmaceutical development and manufacturing facility and an innovation centre in San Francisco, US.